Abstract
Short-term forecasts of the dynamics of COVID-19 in the period up to its decline following mass vaccination was a task that received much attention but proved difficult to do with high accuracy. However, the availability of standardized forecasts and versioned data sets from this period allows for continued work in this area. Here we introduce the Gaussian Infection State Space with Time-dependence (GISST) forecasting model. We evaluate its performance in 1-4 week ahead forecasts of COVID-19 cases, hospital admissions, and deaths in the state of California made with official reports of COVID-19, Google’s mobility reports, and vaccination data available each week. Evaluation of these forecasts with a weighted interval score shows them to consistently outperform a naive baseline forecast and often score closer to or better than a high-performing ensemble forecaster. The GISST model also provides parameter estimates for a compartmental model of COVID-19 dynamics, includes a regression submodel for the transmission rate, and allows for parameters to vary over time according to a random walk. GISST provides a novel, balanced combination of computational efficiency, model interpretability, and applicability to large multivariate data sets that may prove useful in improving the accuracy of infectious disease forecasts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JMD received grant NSF DEB-2027786 from the National Science Foundation (nsf.org).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Analysis was limited to highly aggregated data and therefore no oversight was required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* odea35{at}gmail.com
Data Availability
All relevant data are publicly available at sources cited in the main text and all relevant code is publicly available online.